Sangamo Therapeutics is continuing to sell off its assets under Chapter 11 bankruptcy proceedings, with its ST-503 chronic neuropathic pain program now up for auction.
ST-503 uses an AAV vector to deliver an engineered zinc finger repressor (ZFR), designed to reduce expression of SCN9A, the gene encoding the Nav1.7 sodium channel, which plays a central role in pain signaling. In preclinical studies, a single intrathecal administration of ST-503 reduced Nav1.7 expression and pain hypersensitivity in animal models. The therapy has received fast track designation from the FDA.
According to Sangamo, seven sites have been activated in the phase 1/2 STAND study evaluating the safety and efficacy of ST-503 in patients with SFN, a peripheral neuropathy associated with severe chronic neuropathic pain and significant unmet medical need. SFN has an estimated prevalence of at least 180,000 patients in the U.S.
The auction process is expected to be completed in the fourth quarter of 2026.
Sangamo first announced it bankruptcy filing in June 2026. In August, following a bankruptcy auction, PTC paid $111 million to pick up Sangamo’s most advanced asset, ST-920, a gene therapy for Fabry disease that was submitted for BLA review on a rolling basis in March 2026.. Eli Lilly bought Sangamo's capsid delivery technology (STAC-BBB), zinc finger nuclease, and modular integrase platforms, plus an early-stage AAV-based prion disease program (ST-506), for $50 million in cash.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!